Category Archives: News

European Biotechnology Life Science and Industry Magazine published the article “A pioneering real AI drug discovery technology” describing the approach of SOM Biotech. The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and cost-effective …

La Vanguardia published a press release: “The future of biotechnology: lower-cost treatments in a short period of time”. You can find a short overview of the press release below. SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in …

SOM Biotech announces its participation at the Drug Discovery Innovation Programme event 2020, being held virtually on November 17th. The conference will be chaired by Kevin McAllister, PhD, MBA Chief Scientific Officer. As a keynote speaker, Maria Zimina, PhD. MBA, Business Development Manager, will present “AI Evolutionary Algorithms for the Identification of Non-Structural Analogs: Case …

SOM Biotech presents its drug candidate SOM3355 for the Chorea in Huntington Disease at the XIX Pharma-Biotech Cooperation conference, November 12th 2020. The conference, an initiative of Farmaindustria – the National Trade Association of the Spanish based pharmaceutical industry –  allows companies previously selected for their contribution to innovation, to present their drug development projects to …

SOM Biotech will attend the “BIO-Europe 2020” convention on October 26th – 29th, which will take place digitally due to the pandemic situation. Raúl Insa, CEO of SOM Biotech: “BIO-Europe 2020 is one of the most relevant partnering events for the life science sector. We look forward to meeting with potential partners and qualified investors …

SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020. The poster is entitled “Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections”. It outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of …

SOM Biotech has attended the virtual V Workshop “Duchenne and the Brain” organized by the Duchenne Parent Project Spain on September 7th, on the occasion of the World Duchenne Awareness Day 2020. Gal·la Pericot, R&D Manager of SOM Biotech: “The Duchenne Parent Project Spain is a valuable initiative to encourage collaboration among R&D groups that work on finding …

SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. Eravacycline is an …

Business Insider Spain published the article “The pandemic will trigger investment in biotechnology: the most relevant Spanish startups and the sectors with the greatest potential.”  With biotech companies leading the search for a COVID-19 vaccine, improving antibody detection and diagnosis systems, and searching for new treatments, everything indicates that the sector will emerge stronger and …

SOM Biotech announces the appointment of Alain Duguet Ph.D. as Head of Chemical Manufacturing and Control. Alain Duguet Ph.D. has joined SOM Biotech assuming responsibility for the company´s pharmaceutical development, product manufacturing, and control and compliance with quality requirements. Alain Duguet has extensive experience in pharmaceutical development, from the setting of analytical methods, the testing …